Pathfinders in Biopharma

• MindMed: Rethinking brain health with psychedelic therapy

  Over the last 18 months, MindMed has undergone an extraordinary transformation. It released compelling data for its LSD-based drug MM120, followed by FDA breakthrough designation for MM120 for the treatment of GAD, and strong financial backing. CEO Rob Barrow outlines the company's ambitious goals and the path to potentially transforming mental healthcare at RBC's Global Healthcare Conference.

  --------  

  11:58

  --------

  11:58
• Funding the future of retinal health with Eyepoint

  Eyepoint CFO George Elston provides insights on the evolving space of retinal disease treatment, focusing on capital allocation, medical innovation, industry engagement and financial prudence.

  --------  

  12:13

  --------

  12:13
• How Blackstone Life Sciences is bridging the innovation gap

  Paris Panayiotopoulos, Senior Managing Director at Blackstone Life Sciences, shares how the firm’s broad life sciences strategy has been advancing innovation across the life sciences ecosystem in three key ways: late-stage product financing (Collaboration) and new company creation (Ownership), and non-dilutive financing (Credit and Royalties). He explains how Blackstone is bridging the innovation funding gap through high-conviction partnerships with larger BioPharma and MedTech companies, and targeted investment in late-stage trials.

  --------  

  20:59

  --------

  20:59
• Compass trials mark a milestone moment for the psychedelics sector

  Compass Pathways CEO Kabir Nath believes psilocybin-based therapy could be transformational for patients with treatment-resistant depression—and his company is already preparing to deliver it at scale. Speaking at RBC Capital Markets’ Global Healthcare Conference, Nath shares his vision for Compass and the future of psilocybin therapy for treatment-resistant depression.

  --------  

  12:35

  --------

  12:35
• Cidara’s pursuit of universal flu protection with a single dose

  Every year, flu vaccine manufacturers have to guess what strains to target next season, with varying success. Cidara Therapeutics believes it may have a better alternative. President and CEO Jeff Stein explains how Cidara's laser-like focus on developing CD388, a single-dose antiviral targeting all flu strains, has brought the 40-person company on the verge of a public health breakthrough.Cidara announces positive topline results from its phase 2b NAVIGATE trial evaluating CD388President and CEO Jeff Stein Bio

  --------  

  12:11

  --------

  12:11

More Business podcasts

Trending Business podcasts

About Pathfinders in Biopharma

Pathfinders in Biopharma: Podcasts in Family